SOURCE-LINKED INTELLIGENCE
Multi-omic data driven drug discovery and indication prioritisation platform in oncology
w drug candidates to license IP assets to pharma companies. By 2025, we expect to sign a deal of €25M with a biopharma partner. We will disrupt he oncology market for the benefits of cancer patients. machine learning,personalised medicine,omic analysis,drug discovery
Read original source ↗ Open in workspace
- recordType
- award
- status
- CLOSED
- region
- EU
- value
- 2495788.75
- unit
- EUR
Evidence & attribution
European Commission, CORDIS Horizon Europe project dataset. Metadata adapted.
License: CORDIS reuse policy
First collected: 2026-09-20T00:21:03.701Z. This is not the publication date.